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Activation of JAK2 is implicated in normal hematopoiesis as well as oncogenic transformation. A paper in the
recent issue of Nature demonstrates that phosphorylation of histone H3 by JAK2 releases the transcriptional
repressor HP1a from chromatin, resulting in gene transcription.JAK2 is a nonreceptor tyrosine kinase that
forms a complex with the cytoplasmic
portions of the receptors for growth
hormone, erythropoietin, and related
family members. The transcription factor
STAT5 (signal transducer and activator of
transcription 5) is a major substrate for
JAK2, mediating part of its biological
response. In neoplasms such as polycy-
themia vera where JAK2 is constitutively
activated because of mutation, STAT5
appears to partially drive transformation.
Mice with either JAK2 or STAT5A and
STAT5B gene disruption have
severely disrupted hemato-
poiesis (Hennighausen and
Robinson, 2008; Ihle andGilli-
land, 2007). However, it has
been evident for some time
that STAT5 is not likely to
mediate all of the signaling
activities of JAK2.
Dawson et al. (2009) have
now reported an important
second JAK2-signaling path-
way. The authors found that
35% (14) of the top 40 JAK2-
regulated genes identified in
their study did not contain
a putative STAT5 binding
site. As one example, lmo2
was identified as a major
JAK2-responsive target gene
that is implicated in normal
hematopoiesis and leukemic
transformation, but did not fit
the profile of a STAT5-regu-
lated gene. They found that
JAK2 is localized not only to
the cytoplasm but also to the
nucleus, where it can phos-
phorylate histone H3 at tyro-
sine residue 41 (Y41) (Fig-
ure 1). In cell lines such as
HEL, where JAK2 kinase
activity is constitutively activated by a
JAK2V617F mutation, phosphorylation of
H3Y41was similarly constitutive, whereas
in cell lines with wild-type JAK2,
phosphorylation of H3Y41 was induced
after activation of JAK2 by an appropriate
cytokine. Phosphorylation of the H3Y41
site by JAK2 resulted in release of the
transcriptional repressor heterochromatin
protein 1a (HP1a) from chromatin, result-
ing in transcription of genes repressed
by HP1a, such as lmo2. By contrast, inhi-
bition of JAK2 kinase activity in HEL cells
increased recruitment of HP1a to the
lmo2 promoter, but not to the promoter
of the nearby b2-macroglobulin gene.
They further demonstrate that the phos-
phorylation of histone H3 on Y41 depends
on JAK2 kinase activity via kinase inhibi-
tors and overexpression of JAK2. The
levels of H3Y41 were low in the AML cell
line HL60 with no detectable levels of
active JAK2 as well as in the JAK2-defi-
cient fibrosarcoma cell line g2A. Ectopical
expression of the wild-type JAK2 or
the constitutively active JAK2V617F into
g2A cells increased H3Y41
phosphorylation. Conversely,
H3Y41 phosphorylation was
reduced in HEL cells in re-
sponse to the JAK2 inhibitors
TG101209 and AT9283. It is
not clear from these findings
whether the nuclear pool of
JAK2 isalteredupon thestimu-
lation of its kinase activity or
how nuclear JAK2 gets acti-
vated. A link between JAK2
andHP1a hadbeen previously
reported in Drosophila mela-
nogaster, although STAT pro-
teins were directly involved in
the process in that model
system (Shi et al., 2006).
Activation and phosphory-
lation of STAT5 by JAK2 is
thought to require binding of
JAK2 through its FERM
domain to a growth factor
receptor (Funakoshi-Tago
et al., 2006; Wernig et al.,
2008). Thus the results of
Dawson et al. (2009) open
up the intriguing question
whether nuclear activation of
JAK2 also requires additional
cofactors. It will be interesting
to determine the structural
Figure 1. Model for the Regulation of Transcription by Active JAK2
In hematopoietic cells, JAK2 can be transiently activated through cytokine
mediated receptor ligation or chronically through multiple mechanisms,
including the activating JAK2V617F point mutation. The canonical JAK2
pathway leads to phosphorylation of the STAT5 transcription factor at Y694
within the cytoplasm (Gouilleux et al., 1994). Phosphorylated STAT5 is trans
located to the nucleus and drives dependent gene expression as a transcrip
tional activator. However, through a novel mechanism, active nuclear JAK2
phosphorylates histone H3 at Y41 and thus disrupts the interaction of the
HP1a chromo shadow domain with H3 (Dawson et al., 2009). HP1a is thus
effectively displaced from H3 and, as a consequence, its chromatin silencing
function is disrupted.Cancer Cell 16, November 3, 2009 ª2009 Elsevier Inc. 365
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Previewsrequirements for JAK2 activation in the
nucleus and the process guiding plasma
membrane-bound active JAK2 to the
nucleus. However, basal phosphorylation
of histone H3Y41 would hint at some
redundancy in this pathway that may not
require JAK2.
It has been apparent for some time that
STAT5 cannot be the only major tran-
scriptional effector of JAK2 and other
substrates of this kinase have been char-
acterized with various impact on gene
expression. The identification of histone
H3Y41 as a target of JAK2-dependent
HP1a regulation adds a new dimension
to the field of JAK2 biology. These find-
ings will help to unravel some of the
dynamics within the intricate signaling
networks required for early hematopoi-
esis. As correctly pointed out by Dawson
et al. (2009), the role of the HP1a binding
region in nucleosome mobility and
stability as well as that of HP1a itself in
mitotic recombination may explain somePARsing the Phras
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Defects in conserved signaling pathways
are well known to play key roles in the
origins and behavior of essentially all
cancers. Mutations affecting the Wnt
signaling pathway underlie the pathogen-
esis of cancers, including upwards of
80%–90% of colorectal cancers (CRCs)
(MacDonald et al., 2009). TheWnt proteins
are a conserved family of secreted mole-
culeswith pleiotropic andcontext-specific
effects on cells (MacDonald et al., 2009).
In the canonical or b-catenin-dependent
366 Cancer Cell 16, November 3, 2009 ª200of the genomic instability associated
with malignancies containing active JAK2
(Fernandes et al., 2009; Plo et al., 2008).
Nevertheless, it seems likely that other
factors might regulate HP1a and the
degree of JAK2 requirement is not entirely
clear. It will need to be carefully deter-
mined whether these novel interactions
of JAK2 with histone H3Y41 open up
new opportunities for targeted thera-
peutic approaches that may benefit
patients with hematologic neoplasms or
other malignancies that involve deregu-
lated JAK2 activity. Finally, it is possible
that other members of the Janus kinase
family (JAK1, JAK3, and TYK2) may have
analogous functions in the nucleus and
that should be examined.
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